Conv. Plasma
Nigella Sativa
Vitamin A
Vitamin C
Vitamin D

Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlSaber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Pawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Majeed (DB RCT)66%0.34 [0.01-8.09]ventilation0/451/47CT​1Tau​2 = 0.50; I​2 = 42.9%Early treatment68%0.32 [0.12-0.84]2/26623/26768% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTahmasebi (DB RCT)83%0.17 [0.02-1.32]death1/406/40Hassania.. (DB RCT)-46%1.46 [0.01-329]SpO2 imp.20 (n)20 (n)Tau​2 = 0.00; I​2 = 0.0%Late treatment58%0.42 [0.17-1.03]5/8014/8058% improvementAll studies56%0.44 [0.26-0.75]7/34637/34756% improvement8 curcumin COVID-19 Oct 17, 20211 CT: study uses combined treatmentTau​2 = 0.13; I​2 = 21.1%; Z = 3.03Effect extraction pre-specifiedFavors curcuminFavors control
Database of all curcumin COVID-19 studies. Studies typically use advanced formulations for greatly improved bioavailability. Submit updates/corrections.
Oct 11
Early Majeed et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545 (Peer Reviewed) ventilation, ↓66.2%, p=1.00 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients
Details   RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.
Sep 19
Late Hassaniazad et al., Phytotherapy Research, doi:10.1002/ptr.7294 (Peer Reviewed) no recov., ↑45.7%, p=0.90 A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
Details   Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune re..
Sep 8
Late Chabot et al., Cureus, doi:10.7759/cureus.17829 (Peer Reviewed) Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia
Details   Small case study of 2 patients, showing significant improvement in taste and smell shortly after one dose of a turmeric supplement. Authors note that the risk of one dose is low in healthy individuals not on medications metabolized by cyt..
Jul 9
N/A Panda et al., Medicine, doi:10.1097/MD.0000000000026601 (Peer Reviewed) The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
Details   Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability.
Jun 29
In Vitro Guijarro-Real et al., Foods, doi:10.3390/foods10071503 (Peer Reviewed) (In Vitro) in vitro Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
Details   In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLPro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLPro activity, but did not fully account for the inhibitory effect of turmeric rh..
Jun 19
Early Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 (Peer Reviewed) hosp., ↓85.7%, p=0.24 Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
Details   RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
Jun 17
In Vitro Goc et al., PLOS ONE, doi:10.1371/journal.pone.0253489 (Peer Reviewed) (In Vitro) in vitro Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions
Details   In Vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen fo..
May 28
Early Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 (Peer Reviewed) death, ↓81.8%, p=0.02 Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Details   RCT 140 patients, 70 treated with curcumin and piperine (for absorption), showing faster recovery, lower progression, and lower mortality with treatment. Control group partients also received probiotics. CTRI/2020/05/025482.
May 7
Review Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review) (Peer Reviewed) review Curcumin as a Potential Treatment for COVID-19
Details   Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects.
Mar 28
Late Tahmasebi et al., Life Sciences, doi:10.1016/j.lfs.2021.119437 (Peer Reviewed) death, ↓83.3%, p=0.11 Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
Details   RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin).
Jan 3
Early Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 (Peer Reviewed) progression, ↓94.3%, p=0.001 Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
Details   Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
Nov 16
Early Dound et al., Journal of Clinical Trials, S3:004 (Peer Reviewed) 7-point status, ↓33.3%, p=0.0001 A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19)
Details   RCT 200 COVID-19 positive patients in India, 100 treated with Curcumin, Vitamin C, Vitamin K2-7, and L-Selenomethionine, showing faster recovery with treatment.
Nov 13
Review Kritis et al., Metabolism Open, doi:10.1016/j.metop.2020.100066 (Review) (Peer Reviewed) review The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19
Details   Review of the potential benefits of bromelain and curcumin for COVID-19, and potential synergistic effects of the combination.
Oct 20
Late Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 (Peer Reviewed) death, ↓50.0%, p=0.30 Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Details   Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR..
Apr 24
In Silico Sekiou et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 (Preprint) In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2
Details   In silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.